Search

Exciting day 🤩 Our newly born GIVoM - Gruppo Italiano Virus of Microbes met for the first time! Italians – in the country and abroad 🇮🇹 - working in this field 🧫🦠🧬 will gather every month to share our research and support each other.❗

Technophage, a phage biotech company in Portugal, successfully completed its Phase I/IIa Clinical Trial of TP-102, a phage cocktail for infected diabetic foot ulcers.

The Antibacterial Resistance Leadership Group will begin a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial to examine safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized

From 2018 to 2022, IPATH initiated phage hunts for 265 patients, but 25% couldn't proceed due to lack of phages. IPATH has now partnered with Korean phage company MicrobiotiX; IPATH will screen and send sample isolates to MicrobiotiX, who w

Cole Matrishin (University at Buffalo) and colleagues published a new preprint on how phages are unrecognized players in oral pathogen Porphyromonas gingivalis ecology, contributing to strain-level diversity and the species pangenome. They

In a new GARDP antimicrobial viewpoint piece, Jon Iredell and Jessica Sacher of Phage Australia discuss ways to improve the economics of personalized phage therapy as part of a clinical service, including increasing the number of patients w

The Ibadan Bacteriophage Research Team, an undergraduate SEA-PHAGES team at the University of Ibadan, Nigeria, announces the launch of the 2nd edition of the team’s journal issue, PHAMILIA. This is the very first undergraduate research jour

Steffanie Strathdee, Graham Hatfull, Vivek Mutalik and Robert Schooley wrote a new review of the state of the art in phage therapy, covering biological mechanisms, clinical applications, remaining challenges, and future directions.

University of Nebraska-Lincoln authors show that small protists can consume viruses and grow and divide given only viruses to eat; the ciliate Halteria sp. foraging on chloroviruses shows dynamics similar to other microbial trophic interact

Fixed Phage, a biotechnology company based in Glasgow, has secured £1.5 million in funding to further develop and commercialize its phage technology.

The Phage Australia Clinical Network has published the STAMP Protocol for phage therapy. This is an open-label, single-arm trial investigating a standardised treatment and monitoring protocol for phage therapy. The aim is to recruit 50–100

In a new study published in Frontiers in Cellular and Infection Microbiology, Sheetal Patpatia (University of Helsinki) and colleagues describe how they set up a rapid hydrogel-based liquid phage susceptibility assay (PST) for the selection

In this study, a novel Pseudomonas phage, vB_PaeS_VL1 (VL1), was isolated from urban sewage. Phylogenetic analyses revealed that VL1 is a novel species in the genus Litunavirus of subfamily Migulavirinae. The VL1 is a virulent phage as no g

In this paper, Nale et al. review current progress in Clostridioides difficile phage research. They discuss tested strategies of isolating C. difficile phages directly, and via enrichment methods from various sample types and through antibi

From Phase Genomics via Twitter: Milestone alert! We’re celebrating 150+ papers published using our tech. And there’s a lot to share: our clients made breakthroughs in a broad range of fields from metagenomics to oncology. Here’s a look at

Check out this youtube video of Rob Lavigne’s Phage Oxford 2022 talk.

In a new paper in PLOS Computational Biology, Quentin J. Leclerc (Institut Pasteur) and colleagues use mathematical modelling to investigate the conditions under which phages and antibiotics act in synergy to remove bacteria or drive antimi

A new preprint by Madison Stellfox (University of Pittsburgh) and colleagues reports on the use of phage therapy to treat recurrent E. faecium bloodstream infections in a patient.

A new paper in Nature Communications by Lei Tian (McMaster University) and colleagues describes a new method for producing phage microgels, which could be used as sprayable antimicrobials targeting multidrug-resistant bacteria.

The UK Government's Commons Science and Technology Committee announces the terms of reference for a new inquiry exploring the potential of bacteriophages as an alternative to antibiotics.